UBS AG Reaffirms “Buy” Rating for Mylan N.V. (MYL)
Mylan N.V. (NASDAQ:MYL)‘s stock had its “buy” rating reiterated by equities researchers at UBS AG in a research note issued to investors on Thursday. They currently have a $46.00 price target on the stock. UBS AG’s price target indicates a potential upside of 21.69% from the stock’s previous close.
Several other research firms have also weighed in on MYL. Zacks Investment Research upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Royal Bank Of Canada restated a “hold” rating and issued a $41.00 price objective on shares of Mylan N.V. in a report on Tuesday, June 13th. BidaskClub upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Wells Fargo & Company restated a “market perform” rating and issued a $32.00 price objective (up from $30.00) on shares of Mylan N.V. in a report on Wednesday. Finally, Cowen and Company restated a “market perform” rating and issued a $36.00 price objective (up from $30.00) on shares of Mylan N.V. in a report on Thursday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $42.04.
Shares of Mylan N.V. (NASDAQ MYL) traded up 0.24% on Thursday, hitting $37.89. 8,433,498 shares of the company were exchanged. Mylan N.V. has a 52-week low of $29.39 and a 52-week high of $45.87. The firm’s 50-day moving average is $31.65 and its 200-day moving average is $36.47. The stock has a market capitalization of $20.32 billion, a PE ratio of 30.63 and a beta of 1.30. Mylan N.V. also saw some unusual options trading activity on Wednesday. Investors purchased 10,562 put options on the stock. This is an increase of approximately 461% compared to the typical volume of 1,883 put options.
Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.18 by ($0.08). Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The business had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3 billion. During the same period in the prior year, the company posted $1.16 EPS. The firm’s revenue was up 15.7% on a year-over-year basis. Equities research analysts predict that Mylan N.V. will post $4.52 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. Waldron LP acquired a new position in Mylan N.V. during the first quarter valued at approximately $229,000. UBS Asset Management Americas Inc. lifted its position in Mylan N.V. by 13.7% during the first quarter. UBS Asset Management Americas Inc. now owns 1,179,217 shares of the company’s stock valued at $45,978,000 after buying an additional 142,124 shares in the last quarter. Sei Investments Co. lifted its position in Mylan N.V. by 1.0% during the first quarter. Sei Investments Co. now owns 13,870 shares of the company’s stock valued at $541,000 after buying an additional 134 shares in the last quarter. Blair William & Co. IL lifted its position in Mylan N.V. by 20.3% during the first quarter. Blair William & Co. IL now owns 9,591 shares of the company’s stock valued at $401,000 after buying an additional 1,616 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in Mylan N.V. by 4.3% during the first quarter. Alliancebernstein L.P. now owns 822,534 shares of the company’s stock valued at $32,071,000 after buying an additional 33,666 shares in the last quarter. Hedge funds and other institutional investors own 71.97% of the company’s stock.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.